Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxford Nanopore Technologies has obtained £25m ($41m) funding to develop, validate external technology and to produce capabilities of its proprietary technology for molecular analysis applications that include DNA sequencing and protein analysis.
Subscribe to our email newsletter
The Oxford Nanopore platform technology, GridION, consists of a scalable modular instrument and self-contained consumable cartridge.
GridION is adaptable for the analysis of different types of molecules including DNA and proteins by changing the types of nanopore included in the cartridge.
The grant was funded by existing and new institutional and individual investors from the US and UK, including Lansdowne Partners, IP Group, Invesco Perpetual, Redmile Group, Illumina and other undisclosed investors.
The company has raised £49m since its formation in 2005.
Oxford Nanopore CEO Gordon Sanghera said the investors share their excitement about the Oxford Nanopore DNA sequencing system that is designed to meet the diverse needs of a range of scientific users.
"In addition, last year we noted that the development of our platform technology, GridION, was advanced enough to merit the addition of a new project to develop techniques for electronic protein analysis," Sanghera said.